GL-IL2-138 is a small molecule RNA agent that modulates natural IL-2, allowing for downregulating or upregulating the immune system to fight devastating ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients ...

Tocilizumab significantly reduced 28-day mortality and length of ICU stay in patients with severe COVID-19 pneumonia and low S-spike nAb titers.

PYPD PolyPid Ltd. (NASDAQ:PYPD) is a late clinical stage biopharma company focused on developing locally administered, prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation ...

FDA Protocol Review Completed ~~ Rho, Inc. Selected as Clinical Research Partner ~ SAN DIEGO, CA / ACCESS Newswire / July 16, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company" ...

Patients with knee osteoarthritis who received metformin demonstrated significant reductions in knee pain and increased ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...